Global Pharmaceutical Excipients Market Set To Grow To $8.5bn By 2022

06 August 2018
Pharma

Visiongain’ has launched a new pharma report Global Pharmaceutical Excipients Market Forecast to 2027 : Plant-Based, Animal Chemistry, Mineral, Synthetic, Oral Application, Topical Application, Parental Application, Other Application, Binders, Diluents, Glidants, Disintegrant, Others

The pharmaceutical industry is facing various challenges such as patent cliff, strict regulations and reduced healthcare spending; all these factors are hindering the development of new drugs. Novel excipients offer several opportunities to overcome these challenges. Novel excipients can be used to reformulate approved drugs and also improve the quality and safety of the drugs as well as reducing manufacturing cost. Manufacturers of generic drugs are now mainly focusing on reformulating and reintroducing their products with a cost-effective process to develop super generic drugs and to extent patents. Hence, various important steps are taken by key players such as modification in design and dosage forms, increasing focus on quality by design, and use of excipients in reformulation of drugs.
The lead analyst of the report commented “Pharmaceutical industry is highly dependent on the development and discovery of new molecules for the replacement of old drugs revenue stream that are going towards patent expiry. Therefore, drug formulators and innovators are mainly focusing on developing new chemical entities. Similarly, narrow pipeline of new chemical excipients, increasing preference of manufacturers for the direct compression (DC) process and technological advancement in tablets manufacturing, are some of the other factors that will give opportunity for the development of high-functionality excipients.”

Leading companies featured in the report include Evonik Industries AG, BASF SE, Innophos Holdings Inc., The Lubrizol Corporation, The DOW Chemical Company, Wacker Chemie AG, Ashland Inc.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Rare Diseases Market Report 2021-2031

As lockdowns were imposed in all the countries, diagnosis rates went down in majority of countries during the year hitting the drug sales for some period. Although lockdown measures have been eased up in most countries by mid-year 2020, this trend is expected to continue beyond 2020, stock up of medicines by patients is likely to propel the drug sales in majority of the developed economies, which account for majority of rare diseases.

02 March 2021

Read

Visiongain Publishes Respiratory Inhalers Market Report 2021-2031

Product approval is a major milestone facing all key competitors in the respiratory inhalers market. Several strategies were implemented by key market players between 2015 and Jan 2021.

26 February 2021

Read

Visiongain Publishes Bile Duct Cancer Drugs Market Report to 2031

The global bile duct cancer drug market has been growing considerably owing to the rising incidence and prevalence rate of bile duct cancer patients worldwide, technological advancement in drug development, and healthcare spending.

22 February 2021

Read

Visiongain Publishes Big Data Analytics in Healthcare Market Report to 2031

The global Big Data Analytics in Healthcare market has been growing considerably owing to the rising technological advancement, growing investment, and cohesive government policies.

22 February 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever